As of Aug 25
| -0.25 / -4.61%|
The 2 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 13.00, with a high estimate of 21.00 and a low estimate of 5.00. The median estimate represents a +151.45% increase from the last price of 5.17.
The current consensus among 6 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.